

台灣神經內分泌腫瘤學會 2020 冬季會

“Multimodalities Approach to Neuroendocrine Tumor Management”

時間：2020 年 11 月 28 日 (星期六) 14:30-18:15

地點：高雄漢來大飯店 15F 會展廳 (地址：高雄市前金區成功一路 266 號)

主辦：台灣神經內分泌腫瘤學會

協辦：法商益普生股份有限公司台灣分公司

報名費：會員免費；非會員 1,000 元 (現場繳納)

報到時間：14:00~

Time	Topic	Speaker	Moderator
14:30~14:40	Opening	郭昭宏 院長 高醫小港醫院	
14:40~15:15	The Updated of NET Diagnosis: Endoscopic Intervention, EUS and Molecular Testing	王耀廣 助理教授 高醫附醫 胃腸內科	郭昭宏 院長 高雄市立小港醫院 胃腸內科
15:15~15:50	Surgical Management for NET in KMHU Experiences	莊世昌 主任 高醫附醫 一般外科及消化外科	陳以書 主任 高雄榮總 一般外科
15:50~16:00	Coffee Break		
16:00~16:35	The Clinical Experiences of Somatostatin Analog in pNET & Midgut NET Treatment in CGMHKS	邱泰然 助理教授 高雄長庚醫院 血液腫瘤科	陳彥仰 主任 高雄長庚醫院 血液腫瘤科
16:35~17:10	Key Learnings of NET Management from eESMO Virtual Conference 2020	陳明晃 主任 台北榮民總醫院 腫瘤醫學部	白禮源 主任 中國附醫 血液腫瘤科
17:10~17:50	Key Insights from Latest Evidence of NET Treatment	Dr. Xuan Mai Truong Thanh Global Medical Director Ipsen Pharma	黃燦龍 理事長 台灣神經內分泌腫瘤學會
17:50~18:15	Panel discussion & Closing	ALL	黃燦龍 理事長 台灣神經內分泌腫瘤學會
18:30	台灣神經內分泌腫瘤學會理監事會議暨晚宴 (9F 金冠廳)		

學會教育積分：(申請中)

台灣外科醫學會	台灣內科醫學會
台灣消化系外科醫學會	台灣消化系醫學會
台灣內視鏡外科醫學會	20 分 台灣消化系內視鏡醫學會
中華民國醫用超音波醫學會	中華民國癌症醫學會

Shih-Chang Chuang

Division of General and Digestive Surgery
Department of Surgery
Kaohsiung Medical University Hospital
No. 100, Tzyou 1st Rd. Kaohsiung 807, Taiwan
Office: 886-7-3208172 Fax: 886-7-3216992
chuangsc@cc.kmu.edu.tw

Personal information

- Male
- Date of Birth: Jun 3, 1965
- Place of Birth: Kaohsiung city
- Marital status: Married
- Nationality: Taiwan, ROC

Current position

Since 02/2014 Associate Professor

- Department of Surgery
- Faculty of Medicine, Kaohsiung Medical University

Since 08/2020 Director of General and Digestive Surgery

- Department of Surgery
- Kaohsiung Medical University Hospital

Education

07/1984 - Medicine Bachelor

06/1991 • Kaohsiung Medical University, Taiwan

07/1999 - Medicine Master

06/2002 • Kaohsiung Medical University, Taiwan

07/2007 - Medicine Doctor

06/2014 • Kaohsiung Medical University, Taiwan

Professional experience

1990-1991 Internship

- Kaohsiung Medical University Hospital

1993-1996 Resident

- Department of Surgery
- Kaohsiung Medical University Hospital

1996-1998 Chief Resident

- Department of Surgery
- Kaohsiung Medical University Hospital

1998-2004 Consultant Surgeon

- Division of Hepato-biliary Surgery
- Department of Surgery
- Kaohsiung Medical University Hospital

2000-2001 Visiting Scholar

- Department of Surgery I
- Faculty of Medicine
- Kyushu University, Fukuoka, Japan

2002-2003 Visiting Scholar

- Transplant Center
- University of Virginia Hospital, USA

2004-2007 Director of Operating Room
Consultant Surgeon

- Kaohsiung Municipal Hsiao-Kang Hospital

2007-2012 Consultant Surgeon

- Kaohsiung Medical University Hospital

2012-2014 Director of Surgical Department
Director of Surgical Intensive Care Unit
Consultant Surgeon

- Kaohsiung Municipal Hsiao-Kang Hospital

- 2014-2017 Director of Transplantation Center
Consultant Surgeon
• Kaohsiung Medical University Hospital
- 2016-2018 Director of Transplantation Surgery
Consultant Surgeon
• Kaohsiung Medical University Hospital
- 2018-2019 Secretary of Dean chamber
Consultant Surgeon
• Kaohsiung Medical University Hospital
- 2020-now Director of General and Digestive Surgery
Consultant Surgeon
• Department of Surgery
• Kaohsiung Medical University Hospital

Professional specialities

Hepatobiliary and Pancreatic Surgery
Minimal invasive surgery
Liver transplantation

Professional societies

1. Taiwan Surgical Association (2-3436)
2. Taiwan Surgical Society of Gastroenterology (1162)
3. Taiwan Pancreas Society (0052)
4. Taiwan NeuroEndocrine Tumor Society (038)

CURRICULUM VITAE

Tai-Jan Chiu (邱泰然)

PERSONAL INFORMATION

Birthday: December, 29, 1972

Citizen: Kaohsiung, Taiwan

CONTACT INFORMATION

Tai-Jan Chiu

Department of Oncology, Chang Gung Memorial Hospital, Kaohsiung Medical Center

123, Ta-Pei Rd, Niao-Sung Hsiang, Kaohsiung County, 833 Taiwan

E-mail: chiutaijan@gmail.com

Phone: +886-7-7317123 ext 8303

Mobile: +886975056060, +886918653389

Language: Chinese, Taiwanese, English

Education:

1. Jul-1992~Jun-1999; Kaohsiung Medical University; Kaohsiung, Taiwan
2. An undergraduate Ph.D. of Graduate Institute of Clinical Medical Sciences, Chang Gung University since Sep-2013

Employment Record :

1. From August 1, 2001 to July 31, 2002, as a first-year resident in Department of Internal Medicine of Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan, R.O.C.
2. From September 1, 2002 to August 31, 2004, as a second to third year resident in Department of Internal Medicine of Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R.O.C.
3. From September 1, 2004 to August 31, 2006 as a first to second year fellow in Division of Hemato-Oncology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
4. From September 2006 till now, as an attending physician of Division of Hemato - Oncology, Departments of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung,
5. From February 2011 to January 2013, as a visiting scientist of Department of Molecular and Cellular Oncology of MD Anderson Cancer center

LICENSURES : Physician License:Taiwan License NO: 30745

Internal Medicine: Bordered on 13. Jan. 2004,

Licence number : 006781

Medical Oncology: Bordered on 06.Nov.

Licence number: 96014

PUBLICATIONS

1. **Tai-Jan Chiu**, Yi-Ju Chen, Cheng-Hua Huang. Massive anterior chest wall metastasis of ovarian cancer and prolonged survival after treatment: a case report. **J Reprod Med.** 2008 May;53(5):373-7.
2. **Tai-Jan Chiu**; Jun-Wen Wang; Yi-Ju Chen; Yeh Tang; Cheng-Hua Huang. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan. **Chang Gung Med J.**2009 Jan-Feb;32(1):72-80.
3. Chien-Ting Liu, **Tai-Jan Chiu**, Tai-Lin Huang, Chih-Yen Chien, Fu-Min Fang. Impact of Comorbidity on Survival for Locally Advanced Head and Neck Cancer Patients Treated by Radiotherapy or Radiotherapy plus Chemotherapy. **Chang Gung Med J.** 2010 May-June;33(3):283-291.
4. Yu-Li Su, Chien-Ting Liu, **Tai-Jan Chiu**, Shan-Hsuan Li, Tai-Lin Huang, Yen-Yang Chen, Yen Tang, Kun-Ming Rau, Cheng-Hua Huang Metastatic Mucinous Colorectal Cancer: An Important Subtype of Colorectal Cancer with Poor Response to Chemotherapy and Overall Survival. *J. Cancer Res. Pract.* 26(6),221-230, 2010
5. **Chiu, Tai-Jan**, Chen CH, Chien CY, Li SH, Tsai HT, Chen YJ. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. *J Transl Med.* 2011 Mar 23;9:31
6. Chen YJ, Rau KM, Chien CY, Fang FM, Huang TL, **Chiu, Tai-Jan**. High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma. *Asian Pac J Cancer Prev.* 2011;12(3):649-55
7. Wu Chia-Che, **Tai-jan chiu**, Meng-Chih Lin, Jui-Ling Wang, Kun-Ming Rau, Chen YY, Huang CH*. Pemetrexed as third-line chemotherapy for locally advanced and metastatic non-small cell lung cancer (NSCLC) : *A retrospective analysis.* 2011;27:157-164.

8. Rau KM, Huang CC, **Chiu TJ**, Chen YY, Lu CC, Liu CT, Pei SN, Wei YC. Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. *Exp Ther Med.* 2012 Aug;4(2):231-236.
9. **Chiu TJ**, Chen YJ, Rau KM, Chen CH, Chien CY, Li SH, Tsai HT, Eng HL. Midkine neurite growth-promoting factor 2 expression as a potential prognostic marker of adjuvant therapy in head and neck squamous cell carcinoma. *Biomarkers.* 2013 Oct 28.
10. Hwang CF, Shiu LY, Su LJ, Yu-Fang Yin, Wang WS, Huang SC, **Chiu TJ**, Huang CC, Zhen YY, Tsai HT, Fang FM, Huang TL, Chen CH. Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis. *PLoS One.* 2013 Dec 27;8(12):e84218
11. Ming-Chun Ma, Yen-Yang Chen, Shau-Hsuan Li, Yu F. Cheng, Chih-Chi Wang, **Tai-Jan Chiu**, Sung-Nan Pei, Chien-Ting Liu, Tai-Lin Huang, Chen-Hua Huang, Yu-Li Su, Yen-Hao Chen, Sheng-Nan Lu and Kun-Min Rau. Intraarterial Chemotherapy with Doxorubicin and Cisplatin is Effective for Advanced Hepatocellular Cell Carcinoma. *The Scientific World Journal* Volume 2014 (2014), Article ID 160138, 8 page
12. Li SH, Lin WC, Huang TL, Chen CH, **Chiu TJ**, Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, Su YY, Chuang HC, Chien CY. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. *Head Neck.* 2015 Apr 27
13. Chen CH, Chang AY, Li SH, Tsai HT, Shiu LY, Su LJ, Wang WL, **Chiu TJ**, Luo SD, Huang TL, Chien CY. Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer. *Mol Cancer.* 2015 Apr 12;14:83
14. Sheng-Dean Luo, Yi-Ju Chen, Chien-Ting Liu, Kun-Ming Rau, Yi-Ching Chen, Hsin-Ting Tsai, Chang-Han Chen, **Tai-Jan Chiu**; Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma, *BioMed Research international* 2015; 2015: 508587
15. Yang MC, Wang HC, Hou YC, Tung HL, **Chiu TJ**, Shan YS. Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. *Mol Cancer.* 2015 Oct 12;14(1):179.

16. Su YY, Chien CY, Luo SD, Huang TL, Lin WC, Fang FM, **Chiu TJ**, Chen YH, Lai CC, Hsu CM, Li SH. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. *World J Surg Oncol*. 2016 Mar 22;14:86.
17. Fang FM, Chuang HC, Chou SY, Huang TL, Wang CJ, Lin YT, **Chiu TJ**, Lin WC, Li SH, Su YY, Chien CY. The Therapeutic Benefit of Radical Resection for T4b Oral Cavity Squamous Cell Carcinoma with Partial or Complete Response After Radical Chemo-Intensity-Modulated Radiotherapy (IMRT). *Ann Surg Oncol*. 2016 Dec;23(Suppl 5):866-873.
18. Chen CH, Tsai HT, Chuang HC, Shiu LY, Su LJ, **Chiu TJ**, Luo SD, Fang FM, Huang CC, Chien CY. Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A. *Sci Rep*. 2017 May 2;7(1):1358.
19. **Tai-Jan Chiu**, Sheng-Dean Luo, Chih-Yen Chien, Yan-Ye Su, Tai-Lin Huang, Wei-Che Lin, Fu-Min Fang, Chang-Han Chen, Shun-Yu Su, Shau-Hsuan Li. Treatment Outcome of Patients with Unresectable Stage IVB Head and Neck Squamous Cell Carcinoma Receiving Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil. *International Journal of Head and Neck Science* 1(2): 121-130, 2017
20. Rau KM, Su YL, Li SH, Hsieh MC, Wu SC, Chou FF, **Chiu TJ**, Chen YH, Liu CT. High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy. *Mol Med Rep*. 2017 Nov;16(5):7185-7190. doi: 10.3892/mmr.2017.7555.
21. Ma MC, Chen YJ, **Chiu TJ**, Lan J, Liu CT, Chen YC, Tien HH, Chen YY. Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma. *BMC Cancer*. 2018 Feb 27;18(1):227.
22. **Tai-Jan Chiu**. Combinatorial Methods of Immunotherapy Open New Opportunities in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Review article. *International Journal of Head and Neck Science* 2(1): 5-13, 2018
23. Ma MC, **Chiu TJ**, Lu HI, Huang WT, Lo CM, Tien WY, Lan YC, Chen YY, Chen CH, Li SH. SIRT1 overexpression is an independent prognosticator for patients with esophageal squamous cell carcinoma. *J Cardiothorac Surg*. 2018 Apr 10;13(1):25.

24. **Chiu TJ**, Lu HI, Chen CH, Huang WT, Wang YM, Lin WC, Li SH. Osteopontin Expression Is Associated with the Poor Prognosis in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. *Biomed Res Int*. 2018 Apr
25. Lee PC, Fang YF, Yamaguchi H, Wang WJ, Chen TC, Hong X, Ke B, Xia W, Wei Y, Zha Z, Wang Y, Kuo HP, Wang CW, Tu CY, Chen CH, Huang WC, Chiang SF, Nie L, Hou J, Chen CT, Huo L, Yang WH, Deng R, Nakai K, Hsu YH, Chang SS, **Chiu TJ**, Tang J, Zhang R, Wang L, Fang B, Chen T, Wong KK, Hsu JL, Hung MC. Targeting PKC δ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. *Cancer Cell*. 2018 Dec 10;34(6):954-969.e4. doi: 10.1016/j.ccell.2018.11.007.
26. Wang HC, Lin YL, Hsu CC, Chao YJ, Hou YC, **Chiu TJ**, Huang PH, Tang MJ, Chen LT, Shan YS. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. *Theranostics*. 2019 Sep 23;9(24):7168-7183. doi: 10.7150/thno.36830. eCollection 2019.
27. Luo SD, Chen WC, Wu CN, Yang YH, Li SH, Fang FM, Huang TL, Wang YM, **Chiu TJ**, Wu SC. Low-Dose Aspirin Use Significantly Improves the Survival of Late-stage NPC: A Propensity Score-Matched Cohort Study in Taiwan. *Cancers (Basel)*. 2020 Jun 12;12(6):E1551. doi: 10.3390/cancers12061551.
28. **Chiu TJ**, Hsieh MJ, Lin YC, Weng CC, Weng YT, Hsiao CC, Cheng KH. Inactivation of APC Induces CD34 Upregulation to Promote Epithelial-Mesenchymal Transition and Cancer Stem Cell Traits in Pancreatic Cancer. *Int J Mol Sci*. 2020 Jun 23;21(12):E4473. doi: 10.3390/ijms21124473.
29. Tsai MH, Chuang HC, Lin YT, Lu H, Fang FM, Huang TL, **Chiu TJ**, Li SH, Chien CY. Predictors of hospital expenses and hospital stay among patients undergoing total laryngectomy: Cost effectiveness analysis. *PLoS One*. 2020 Jul 16;15(7):e0236122. doi:10.1371/journal.pone.0236122. eCollection 2020.

Curriculum Vitae

Name :

Ming-Huang Chen MD., Ph.D.

Business Address :

No. 201, Section 2, Shih-Pai Rd, Taipei, 11217, Taiwan

Professional Experience :

2017-present, Attending physician, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2017-present Associate Professor, National Yang-Ming University, Taiwan

2017, Visitor, National Cancer Center, Tokyo, Japan

2011, Visitor, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (USA)

Education and medical Training :

<Education>

2002, Bachelor of Medicine, China Medical University, Taiwan

2013, Ph.D., Institute of Clinical Medicine, National Yang-Ming University, Taiwan

<Medical training>

2005-2008 Fellowship in Division of Hematology & Oncology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2002-2005 Residency, Department of Internal Medicine

2001-2002 Internship, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

Board Certification :

Board of Oncology

Board of Hematology

Board of the Internal Medicine

Board of Hospice care

Board of Bone Marrow Transplantation

Memberships :

The Hematology Society of Taiwan

The Chinese Oncology Society

The Society of Internal Medicine

American Society of Clinical Oncology

European Neuroendocrine Tumor Society

Study Experiences

IIT trial

1. **Chen MH**, et al. [A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial.](#) *Medicine (Baltimore)*. 2016 Jan;95(3):e2565.

2. **Chen MH, et al.** An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects with Poorly Differentiated Neuroendocrine Carcinomas (2019 ASCO abstract, *The Oncologist* 2019, under revision)

Publications (only first author or corresponding author):

Chen MH, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, Yang MH, Chao Y. Combined MSI and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) might be a more promising immune biomarker in Colorectal Cancer *Oncologist*. 2019. [Epub ahead of print]

Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y, Yeh CN. [ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.](#) *Clin Cancer Res*. 2016 Aug 15;22(16):4225-35.

Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang KC, Yeh TS, **Chen MH***, **Yeh CN**. MET-RON dual inhibitor, BMS-777607, suppresses cholangiocarcinoma cell growth, and MET-RON upregulation indicates worse prognosis for intra-hepatic cholangiocarcinoma patients. *Oncol Rep*. 2018 Sep;40(3):1411-1421.

Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y, **Chen MH**. [Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.](#) *Int J Biol Sci*. 2016 Nov 25;12(12):1523-1532.

Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN. [Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.](#) *Oncotarget*. 2015 Sep 15;6(27):23594-608.

Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. *Oncotarget*. 2014;5:2372-89.

Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, Lei HJ, Hsiao M, Huang SF, Huang CY, Chau GY. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. *Ann Surg Oncol*. 2013;20:616-24.

Chen MH, Lin KJ, Yang WLR, Kao YW, Chen TW, Chao SC, Chang PMH, Liu CY, Tzeng CH, Chao Y, Chen MH,

Yeh CN, Huang CYF. Gene Expression-Based Chemical Genomics Identifies Heat Shock Protein 90 Inhibitors as Potential Therapeutic Drugs in Cholangiocarcinoma. *Cancer*. 2013;119:293-303.

Chen MH, Yeh YC, ShyrYM, Jan YH, Chao Y, Li CP, Wang SE, Tzeng CH, Chang PMH, Liu CY, Chen MH, Hsiao M, Huang CYF. Expression of Gremlin 1 Correlates with Increased Angiogenesis and Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors. *Journal of Gastroenterology*. 2013;48:101-8.

Chen MH, Yang WL, Lin KT, Liu CH, Liu YW, Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM, Kao CY, Huang CY. [Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma](#). *PLoS One*. 2011;6:e27186.

Chen MH, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS. VEGF -460T→C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. *Pharmacogenomics J*. 2011;11:227-36.

Curriculum Vitae

Name :

Ming-Huang Chen MD., Ph.D.

Business Address :

No. 201, Section 2, Shih-Pai Rd, Taipei, 11217, Taiwan

Professional Experience :

2017-present, Attending physician, Department of Oncology, Tai pei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2017-present Associate Professor, National Yang-Ming University, Taiwan

2017, Visitor, National Cancer Center, Tokyo, Japan

2011, Visitor, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (USA)

Education and medical Training :

<Education>

2002, Bachelor of Medicine, China Medical University, Taiwan

2013, Ph.D., Institute of Clinical Medicine, National Yang-Ming University, Taiwan

<Medical training>

2005-2008 Fellowship in Division of Hematology & Oncology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2002-2005 Residency, Department of Internal Medicine

2001-2002 Internship, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

Board Certification :

Board of Oncology

Board of Hematology

Board of the Internal Medicine

Board of Hospice care

Board of Bone Marrow Transplantation

Memberships :

The Hematology Society of Taiwan

The Chinese Oncology Society

The Society of Internal Medicine

American Society of Clinical Oncology

European Neuroendocrine Tumor Society

Study Experiences

IIT trial

1. Chen MH, et al. A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial. *Medicine (Baltimore)*. 2016 Jan;95(3):e2565.

2. Chen MH, et al. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects with Poorly Differentiated Neuroendocrine Carcinomas (2019 ASCO abstract, *The Oncologist* 2019, under revision)

Publications (only first author or corresponding author):

Chen MH, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, Yang MH, Chao Y. Combined MSI and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) might be a more promising immune biomarker in Colorectal Cancer Oncologist. 2019. [Epub ahead of print]

Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y, Yeh CN. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. *Clin Cancer Res*. 2016 Aug 15;22(16):4225-35.

Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang KC, Yeh TS, **Chen MH***, **Yeh CN.** MET-RON dual inhibitor, BMS-777607, suppresses cholangiocarcinoma cell growth, and MET-RON upregulation indicates worse prognosis for intra-hepatic cholangiocarcinoma patients. *Oncol Rep*. 2018

Sep;40(3):1411-1421.

Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y, **Chen MH**. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. *Int J Biol Sci*. 2016 Nov 25;12(12):1523-1532.

Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. *Oncotarget*. 2015 Sep 15;6(27):23594-608.

Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. *Oncotarget*. 2014;5:2372-89.

Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, Lei HJ, Hsiao M, Huang SF, Huang CY, Chau GY. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. *Ann Surg Oncol*. 2013;20:616-24.

Chen MH, Lin KJ, Yang WLR, Kao YW, Chen TW, Chao SC, Chang PMH, Liu CY, Tzeng CH, Chao Y, Chen MH, Yeh CN, Huang CYF. Gene Expression-Based Chemical Genomics Identifies Heat Shock Protein 90 Inhibitors as Potential Therapeutic Drugs in Cholangiocarcinoma. *Cancer*. 2013;119:293-303.

Chen MH, Yeh YC, ShyrYM, Jan YH, Chao Y, Li CP, Wang SE, Tzeng CH, Chang PMH, Liu CY, Chen MH, Hsiao M, Huang CYF. Expression of Gremlin 1 Correlates with Increased Angiogenesis and Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors. *Journal of Gastroenterology*. 2013;48:101-8.

Chen MH, Yang WL, Lin KT, Liu CH, Liu YW, Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM, Kao CY, Huang CY. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. *PLoS One*. 2011;6:e27186.

Chen MH, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS. VEGF – 460T→C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. *Pharmacogenomics J*. 2011;11:227-36.